Adenoid Cystic Carcinoma

Oncology
7
Pipeline Programs
6
Companies
7
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
2
5
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
375%
Monoclonal Antibody
125%
+ 3 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

E
EisaiChina - Liaoning
2 programs
2
LenvatinibPhase 2Small Molecule1 trial
LenvatinibPhase 2Small Molecule1 trial
Active Trials
NCT04209660Active Not Recruiting64Est. Dec 2026
NCT02780310Active Not Recruiting33Est. May 2026
Pfizer
PfizerNEW YORK, NY
1 program
1
AG-013736Phase 21 trial
Active Trials
NCT01558661Completed33Est. Aug 2016
HitGen
HitGenChina - Chengdu
1 program
1
HG146Phase 21 trial
Active Trials
NCT06781567Recruiting140Est. Jun 2029
Elevar Therapeutics
Elevar TherapeuticsKorea - Seoul
1 program
1
RivoceranibPhase 2Small Molecule1 trial
Active Trials
NCT04119453Terminated80Est. Jun 2023
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
1
CetuximabPhase 1/2Monoclonal Antibody1 trial
Active Trials
NCT01192087Unknown49Est. Jul 2017
Remix Therapeutics
Remix TherapeuticsMA - Watertown
1 program
1
REM-422Phase 1/21 trial
Active Trials
NCT06118086Recruiting100Est. Jun 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
HitGenHG146
EisaiLenvatinib
Elevar TherapeuticsRivoceranib
EisaiLenvatinib
PfizerAG-013736
Remix TherapeuticsREM-422
Heidelberg PharmaCetuximab

Clinical Trials (7)

Total enrollment: 499 patients across 7 trials

NCT06781567HitGenHG146

Clinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma

Start: Dec 2024Est. completion: Jun 2029140 patients
Phase 2Recruiting
NCT04209660EisaiLenvatinib

Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers

Start: Jun 2020Est. completion: Dec 202664 patients
Phase 2Active Not Recruiting
NCT04119453Elevar TherapeuticsRivoceranib

A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)

Start: Jan 2020Est. completion: Jun 202380 patients
Phase 2Terminated
NCT02780310EisaiLenvatinib

Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma

Start: May 2016Est. completion: May 202633 patients
Phase 2Active Not Recruiting
NCT01558661PfizerAG-013736

Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma

Start: Mar 2012Est. completion: Aug 201633 patients
Phase 2Completed
NCT06118086Remix TherapeuticsREM-422

Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma

Start: Dec 2023Est. completion: Jun 2027100 patients
Phase 1/2Recruiting
NCT01192087Heidelberg PharmaCetuximab

Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy

Start: Jun 2012Est. completion: Jul 201749 patients
Phase 1/2Unknown

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
9m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
9m ago

Office Administrator

SystImmune
9m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
19m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
23m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
23m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 499 patients
6 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)